Microbiome Report for Week Ending 9/29/18

Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer

Second Genome, Inc., a clinical-stage company focused on the development of novel therapeutics identified through microbiome science, today announced the appointment of Karim Dabbagh, Ph.D., as president, chief executive officer, and a member of the company's board of directors.